{"entity":{"id":"nct06942234","kind":"trial","name":"Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer","aka":[],"tldr":"A phase 1/2 trial of JSKN016, Capecitabine, Eribulin and Pembrolizumab in advanced solid tumours, run by Jiangsu Alphamab Biopharmaceuticals Co., Ltd, now recruiting.","summary":"Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer is a phase 1/2 interventional study registered as NCT06942234 by Jiangsu Alphamab Biopharmaceuticals Co., Ltd, with 180 participants planned, started 2025-06-01 and due to reach its primary completion in 2027-06-30. Interventions recorded: JSKN016, Capecitabine, Paclitaxel (albumin bound), Eribulin and Pembrolizumab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06942234","url":"https://clinicaltrials.gov/study/NCT06942234"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["jskn016","capecitabine","eribulin","pembrolizumab"],"companies":["alphamab"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06942234","phase":"1/2","setting":"The Multicenter, Open-label, Single-arm, Multi-cohort Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of JSKN016 in Combination Therapy in Chinese Participants With Inoperable Locally Advanced or Metastatic HER2-negative Breast Cancer","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","enrolled":180,"outcomes":[]},"route":"/trials/nct06942234/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"eribulin","kind":"drug","name":"Eribulin","route":"/drugs/eribulin/"},{"id":"jskn016","kind":"drug","name":"JSKN016","route":"/drugs/jskn016/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"alphamab","kind":"company","name":"Alphamab Oncology","route":"/companies/alphamab/"}]}}